Delcath Systems (DV3R) AI Stock Analysis
Delcath Systems
(Stuttgart:DV3R)
No summary available
Delcath Systems (DV3R) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 502.79M
- Dividend Yield
- ―
- Average Volume (3M)
- 155
- Price to Earnings (P/E)
- 1317.3
- Beta (1Y)
- 1.03
- Revenue Growth
- 26.94%
- EPS Growth
- -75.77%
- Country
- Germany
- Employees
- 156
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Delcath Systems Business Overview & Revenue Model
Company Description
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepa...
Delcath Systems Earnings Call Summary
The call presents a balanced mix of positive commercial and clinical momentum (record new patient starts, robust volume growth, encouraging CHOPIN data driving adoption, solid revenue growth and strong cash balance) alongside meaningful near-term operational and financial headwinds (slower-than-expected site activations and trial enrollment, higher R&D and SG&A spend, a quarter-over-quarter decline in adjusted EBITDA and a small net loss, plus European reimbursement constraints and seasonality risks). Management remains optimistic about hitting at least $100M in revenue for 2026 and returning to positive adjusted EBITDA for the year, but several execution and enrollment risks temper the outlook.
Q1-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided to at least $100 million in total 2026 revenue (driven by an expected 20% increase in HEPZATO kit volume vs. 2025), with gross margins forecast at 85–87% and the company expecting to report positive adjusted EBITDA for the remainder of the year; Q1 results supporting guidance included $25.0M total revenue (HEPZATO kit $23.3M, CHEMOSAT $1.7M), Q1 gross margin 85% (vs. 86% a year ago), Q1 adjusted EBITDA $3.4M (vs. $7.6M YA), $89.3M cash and investments with no debt, $0.9M cash from operations, and ~300k shares bought for ~$3M in Q1 ( ~$9M repurchased to date under a $25M buyback); operational assumptions include seasonality similar to 2025 (Q3/Q4 softness), a revised site activation plan of 37 active centers in 2026 (40 by Q1 2027), Q1 new patient starts ~0.7 per site per month, Q1 volume growth +36% YoY (mid‑20% Q1 over Q4), R&D spending now expected to rise ~70–75% YoY (previously guided ~90%) with Q2 R&D ≈20% above Q1 and ~10% above thereafter, and SG&A ~60% higher vs. 2025 with Q2 SG&A ≈10–15% above Q1.
Delcath Systems Risk Analysis
Delcath Systems disclosed 60 risk factors in its most recent earnings report. Delcath Systems reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksDelcath Systems Peers Comparison
Overall Rating
TMDX68Neutral
PEN67Neutral
NVCR53Neutral
TLSI45Neutral
SRTS44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TMDX | 68Neutral | $2.52B | 16.42 | 32.97% | ― | 25.82% | 108.84% |
| PEN | 67Neutral | $12.71B | 80.48 | 10.44% | ― | 16.98% | -5.62% |
| NVCR | 53Neutral | $1.71B | -12.78 | -35.81% | ― | 12.94% | 33.87% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TLSI | 45Neutral | $239.53M | -2.71 | 273.71% | ― | 25.25% | -9.85% |
| SRTS | 44Neutral | $53.50M | -3.11 | -34.09% | ― | -53.40% | -1719.88% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:DV3R | Delcath Systems, Inc. | 12.87 | 5.52 | 75.03% | |
| PEN | Penumbra Inc. | 319.21 | 48.66 | 17.99% | |
| NVCR | NovoCure Ltd. | 13.28 | 2.01 | 17.83% | |
| SRTS | Sensus Healthcare, Inc. | 2.86 | -1.48 | -34.10% | |
| TMDX | Transmedics Group | 88.24 | -34.15 | -27.90% | |
| TLSI | Trisalus Life Sciences, Inc. | 3.25 | -0.75 | -18.75% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.